OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis $0.09 -0.01 (-7.29%) As of 03/11/2025 12:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest About Guided Therapeutics Stock (OTCMKTS:GTHP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Guided Therapeutics alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.1652-Week Range$0.06▼$0.23Volume11,293 shsAverage Volume16,554 shsMarket Capitalization$5.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Read More… Remove Ads Guided Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreGTHP MarketRank™: Guided Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Guided Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Guided Therapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guided Therapeutics is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Guided Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Guided Therapeutics has been sold short.Short Interest Ratio / Days to CoverGuided Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guided Therapeutics has recently increased by 40.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuided Therapeutics does not currently pay a dividend.Dividend GrowthGuided Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Guided Therapeutics has been sold short.Short Interest Ratio / Days to CoverGuided Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guided Therapeutics has recently increased by 40.82%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Guided Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GTHP on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Guided Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.69% of the stock of Guided Therapeutics is held by institutions.Read more about Guided Therapeutics' insider trading history. Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHP Stock News HeadlinesCeriBell (NASDAQ:CBLL) and Guided Therapeutics (OTCMKTS:GTHP) Financial SurveyMarch 8, 2025 | americanbankingnews.comGuided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in ChinaOctober 22, 2024 | finance.yahoo.comForget the chainsaw … Here’s DOGE’s next moveDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faster than most people thought … Clearing out waste and inefficiency in our government.March 12, 2025 | Weiss Ratings (Ad)Guided therapeutics director buys shares worth $150,000October 4, 2024 | investing.comGuided Therapeutics Inc (GTHP)August 21, 2024 | investing.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | msn.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsFebruary 20, 2024 | finance.yahoo.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsFebruary 20, 2024 | businesswire.comSee More Headlines GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed this year? Guided Therapeutics' stock was trading at $0.15 at the start of the year. Since then, GTHP shares have decreased by 40.7% and is now trading at $0.0890. View the best growth stocks for 2025 here. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guided Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Value Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Warner Bros. Discovery (DISCA) and Enbridge (ENB). Company Calendar Today3/12/2025Next Earnings (Estimated)3/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolOTCMKTS:GTHP CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,490,000.00 Net MarginsN/A Pretax Margin-5,660.53% Return on EquityN/A Return on Assets-151.93% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.07 Sales & Book Value Annual Sales$100,000.00 Price / Sales58.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-0.68Miscellaneous Outstanding Shares65,488,000Free Float21,673,000Market Cap$5.83 million OptionableNot Optionable Beta0.50 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:GTHP) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guided Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.